These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 22941880)
1. Global effort against rare and orphan diseases. Harari S; Cottin V; Humbert M Eur Respir Rev; 2012 Sep; 21(125):171-2. PubMed ID: 22941880 [No Abstract] [Full Text] [Related]
2. Why we should care about ultra-rare disease. Harari S Eur Respir Rev; 2016 Jun; 25(140):101-3. PubMed ID: 27246584 [TBL] [Abstract][Full Text] [Related]
3. Rare pulmonary diseases: a common fight. Harari S; Humbert M Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28877977 [TBL] [Abstract][Full Text] [Related]
4. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Harari S; Humbert M; Blasi F; Collard HR; Matucci-Cerinic M; Simonneau G; Vancheri C; Wells AU; Cottin V Eur Respir Rev; 2015 Sep; 24(137):375-7. PubMed ID: 26324798 [TBL] [Abstract][Full Text] [Related]
5. Rare pulmonary disease and orphan drugs: a path to the future. Harari S; Adir Y; Humbert M Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578214 [TBL] [Abstract][Full Text] [Related]
6. Controversies and Evolving Concepts in Orphan Lung Diseases. Gupta N; Ryu JH Semin Respir Crit Care Med; 2020 Apr; 41(2):175-176. PubMed ID: 32279288 [No Abstract] [Full Text] [Related]
7. A Global Approach to Rare Diseases Research and Orphan Products Development: The International Rare Diseases Research Consortium (IRDiRC). Cutillo CM; Austin CP; Groft SC Adv Exp Med Biol; 2017; 1031():349-369. PubMed ID: 29214582 [TBL] [Abstract][Full Text] [Related]
8. Rare lung disease and orphan drug development. Spagnolo P; du Bois RM; Cottin V Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246 [TBL] [Abstract][Full Text] [Related]
9. Future perspectives on rare pulmonary diseases and rare presentations of common disorders. Harari S; Humbert M; Cottin V Eur Respir Rev; 2013 Sep; 22(129):199-201. PubMed ID: 23997045 [No Abstract] [Full Text] [Related]
10. [Orphan drugs. Drugs for treatment of rare diseases]. Hennemann A Med Monatsschr Pharm; 2004 Aug; 27(8):256-9. PubMed ID: 15382448 [No Abstract] [Full Text] [Related]
12. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Luisetti M; Balfour-Lynn IM; Johnson SR; Miravitlles M; Strange C; Trapnell BC; van Bronswijk H; Vogelmeier C Respir Med; 2012 Jun; 106(6):759-68. PubMed ID: 22414566 [TBL] [Abstract][Full Text] [Related]
13. Worldwide collaboration for orphan drug designation. Mariz S; Reese JH; Westermark K; Greene L; Goto T; Hoshino T; Llinares-Garcia J; Sepodes B Nat Rev Drug Discov; 2016 Jun; 15(6):440-1. PubMed ID: 27245396 [No Abstract] [Full Text] [Related]
15. Victory for a rare alliance. Lancet Respir Med; 2013 Aug; 1(6):423. PubMed ID: 24429225 [No Abstract] [Full Text] [Related]
16. Orphan products: hope for people with rare diseases. Rados C FDA Consum; 2003; 37(6):10-5. PubMed ID: 14986582 [No Abstract] [Full Text] [Related]
17. Management of rare diseases in respiratory medicine. Johnson SR Clin Med (Lond); 2007 Oct; 7(5):447-8. PubMed ID: 17990708 [No Abstract] [Full Text] [Related]
18. European researchers, drug companies join forces against rare diseases. Bosch X JAMA; 2005 Oct; 294(16):2014-5. PubMed ID: 16249407 [No Abstract] [Full Text] [Related]
19. A new era of hope for the world's most neglected diseases. The PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790 [TBL] [Abstract][Full Text] [Related]